TOGETHER
Diagenics acquires promising patents or licenses, enters into collaborations or joint ventures, and issues licenses to high-performance partners. It is our objective to selectively apply our know-how and our capital in order to obtain a high return on investment. Based on analysis and recommendations of our Scientific & Medical Advisory Boards, our internationally experienced executives enter into negotiations with our partners worldwide. Their goal is to apply the specific competence of Diagenics in an effective and profitable manner. This leads to development of innovative models, which promote progress in biotechnology and create sustainable values for all parties involved. OUR PHILOSOPHY FOR ALLIANCES AND COOPERATIONSOur partnerships' philosophy is based upon integrity and fair business practices. We shall regularly update our partners on achieving all milestones as agreed upon. All efforts will be focused to get the product to the market as soon as possible while keeping the highest possible quality standards. Milestones will include product development prototype design and optimization pilot production, approvals by FDA, EMEA, MH&W and Total Quality Management criteria. For further information see |
Produkte
DIACORDON - POCT
POINT-OF-CARE TEST
The Point Of Care Test (POCT) is the successor of the ELISA Test and an important supplement for the emergency ambulances. It is a quick and qualitative test for making the first decisions. Point Of Care Tests are always advantageous, since they can provide a diagnosis without the laboratory support.
DIACORDON™ POCT is a stripe test (lateral flow), which also functions on the GPBB basis. Its various layers are plated with small traces of monoclonal catch-antibody of GPBB. Another antibody, responsible for the colouring, is applied on the other side. Once the blood sample runs on the absorbent strap on the antibody track, GPBB is caught by the antibodies and made visible with the help of the antibody colouring. 50 µl are enough to gain a solid result. The time for testing only takes about 15 minutes.
Until now there is no early and reliable heart specific test. Therefore, it is very difficult for doctors to rule out an infarction incidence without invasive diagnostics. Diagenics offers its patented GPBB blood test for an indication group, which knows no other alternatives. Thus, DIACORDON™ is progressive in the field of heart diseases diagnostics.
Another interesting patient group endorses those who had an open heart operation and who often suffer from a destruction of the heart muscle cells under use of a heart-lung machine. DIACORDON™ can help monitoring these patients within the first 12 to 18 hours (as long as GPBB is traceable) after the operation.
The well defined goal of Diagenics is to establish DIACORDON™ as a “gold standard” for the diagnosis and monitoring of myocardial ischemia. Once the first results can be confirmed, the test can be initiated for use as a rapid test in ambulances, in emergency rooms, in doctor offices or next to the patient bed.
The test is simple, fast, safe, dependable and sensitive. At the moment there are discussions with leading active pharmaceutical companies concerning its marketing worldwide.
DIACORDON - ELISA
LABORATORY TEST
DIACORDON™ is a blood test for the early detection of cardiac infarction. It works on an enzyme basis and can detect Glycogen-Phosphorylase Isoenzym BB (GPBB) via an antibody owned by Diagenics.
The enzyme GPBB enters the bloodstream as soon as a myocardial ischemia occurs. In the long run such an insufficient oxygen supply leads to a necrosis of the affected cells and/or eventually to an infarction. Moreover, the detection of GPBB in the blood provides information about the progress of the coronary syndromes (including unstable angina pectoris) and classic cases of heart attack. In this way it contributes decisively to the diagnosis of heart infarction patients.
There are already markers, such as myoglobin and troponin, which contribute to the diagnosis and are routinely applied in cases of a myocardial infarction. Myoglobin, however, has the disadvantage of not being heart specific. It can also be detected after damages of the skeletal muscles or after acute renal failure and thus does not give a clear answer. Troponin, on the other hand, is heart specific, but can only be detected three to six hours after the first symptoms (chest pain).
GPBB is not only heart specific but also early detectable, i.e. within the first hour. For the case of acute coronary syndromes this is a vital advantage, since a quick and exact diagnosis can save lives.
|
Alliances
|
|